What are the DHHS guidelines for treatment-naive patients with HIV infection?

Updated: Jul 27, 2020
  • Author: Shelley A Gilroy, MD, FACP, FIDSA; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print
Answer

The December 2019 DHHS guideline [11] lists the below regimens as "recommended for most" for treatment-naive patients.

INSTI-based regimens are as follows:

  • Bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) (single-tablet regimen)
  • Dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) (single-tablet regimen) - Only for patients who are HLA-B*5701–negative
  • Dolutegravir plus tenofovir disoproxil fumarate/emtricitabine OR tenofovir alafenamide/emtricitabine (two-tablet regimen)
  • Dolutegravir/lamivudine (DTG/3TC) (single-tablet regimen) - Avoid in patients with an HIV viral load of more than 500,000 copies/mL, patients with HBV co-infection, and patients in whom HIV NRTI resistance testing results are unavailable prior to initiation.
  • Raltegravir plus tenofovir disoproxil fumarate/emtricitabine OR tenofovir alafenamide/emtricitabine

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!